Print Page | Close Window

Corporate Profile

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Recent Press Releases

January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus InfectionPrinter Friendly Version 

Upcoming Events

Tuesday, February 7, 2017 4:30 p.m. ET
Fourth Quarter 2016 Gilead Sciences Earnings Conference Call
LocationFoster City, CA
Monday, February 13, 2017 through Friday, February 17, 2017
Conference on Retroviruses and Opportunistic Infections (CROI)
LocationSeattle, WA

Most Viewed Links

Updated 01/21/17
1.SEC Filings
3.Annual Reports
4.Stock Information
5.Fundamentals - Snapshot
* Data collected 01/13/17 - 01/20/17

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.